Young blood/es

From H+Pedia
Revision as of 10:36, 12 May 2021 by George1989 (talk | contribs) (Created page with "Sangre joven '' 'es sangre de un organismo joven. Los estudios han demostrado efectos regenerativos en ratones viejos cuya sangre se intercambió con sangre joven. Sin embargo...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Other languages:
English • ‎español

Sangre joven 'es sangre de un organismo joven. Los estudios han demostrado efectos regenerativos en ratones viejos cuya sangre se intercambió con sangre joven. Sin embargo, la investigación sugiere que esto se debe al acceso circulatorio a los órganos de los donantes jóvenes y a la dilución de la sangre vieja, más que al rejuvenecimiento por la sangre joven. Los controvertidos ensayos de transfusión de sangre joven con seres humanos han tenido resultados poco claros.


Multiple studies have shown positive effects in old mice who have undergone parabiosis, the connection of circulatory systems, with young mice. However, young mice with blood from old mice see negative effects more prominent than benefits to old mice with young blood.

Some lesser benefit, such as muscle regeneration, has also been seen in old mice who have undergone non-parabiotic blood exchange with young mice. Researchers suggested that the parabiosis might have been more effective due to access to the young mice's organs.[1]

A more recent study has shown that diluting old blood plasma with saline was at least as rejuvenating as non-parabiotic blood exchange. The researchers suggest that this is due to simply removing harmful factors in old blood, thus giving an explanation of the benefits in the non-parabiotic exchange other than rejuvenating factors in young blood.[2]


Human trials

Biotech startup Ambrosia ran a human trial from 2016 to 2018.[3] This was criticised for its risk to participants, requirement for participants to pay thousands of dollars, lack of a control group, and lack of published result data despite the declared intention to publish them.[4] Additionally, a 65-year-old participant died the month after the conclusion of the study, which was initially denied but later admitted by Ambrosia's founder.[5]

Another trial was started in 2018 by the Maharaj Institute with estimated completion in 2023. Its plan is to give monthly transfusions of blood plasma from young donors to old and frail participants.[6] The trial also has no placebo group and asked for payment to participate.[7]

The Young Blood Institute have also run trials with blood plasma.[8]


References

  1. Rebo, J; Mehdipour, M; Gathwala, R; et al (22 November 2016). "A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood". Nature Communications. 7 (13363). doi:10.1038/ncomms13363
  2. Mehdipour, M; Skinner, C; Wong, N; Lieb, M; Liu, C; Etienne, J; Kato, C; Kiprov, D; Conboy, M J; Conboy, I M (30 May 2020). "Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin". Aging. 12 (10). doi:10.18632/aging.103418
  3. "Young Donor Plasma Transfusion and Age-Related Biomarkers". ClinicalTrials.gov.
  4. Liebelson, Dana; Cook, Jesselyn (29 December 2018). "He Hawks Young Blood As A New Miracle Treatment. All That's Missing Is Proof." HuffPost.
  5. Cook, Jesselyn (3 October 2019). "Notorious ‘Young Blood’ Doctor Claims Dead Patient Faked His Own Death". HuffPost.
  6. "Safety, Efficacy of FFP From Healthy Donors to AmeliorateFrailty and Enhance Immune Function in Older Individuals". ClinicalTrials.gov.
  7. Robbins, Rebecca (2 March 2018). "Young-Blood Transfusions Are on the Menu at Society Gala". STAT.
  8. Basu, Tanya; Weill, Kelly (22 February 2019). "FDA Warns: Don't Give These Companies Your 'Young Blood'". The Daily Beast.


External links